RHAPSODY

Assessing risk and progression of prediabetes and type 2 diabetes to enable disease modification
RHAPSODY logo

FACTS & FIGURES

Start Date
End Date
Call
IMI2 - Call 3
Grant agreement number
115881

Contributions
IMI Funding
8 130 000
EFPIA in kind
6 882 049
Other
606 625
Total Cost15 618 674

Summary

Improving diabetes prevention and treatment is the ultimate goal of the RHAPSODY project. Type 2 diabetes affects 285 million people globally and that number is rising fast. RHAPSODY brings together experts from universities, large pharmaceutical companies and biotechs. Their goal is to add to our understanding of the factors that drive the progression of pre-diabetes to diabetes, and the deterioration of the condition of people with diabetes. RHAPSODY aims to develop novel biological markers that will aid in the diagnosis of type 2 diabetes, and the identification of different sub-groups of patients. This information will also help to inform clinical trial design and the development of new strategies to prevent and treat diabetes.

Participants Show participants on map

EFPIA companies
  • Institut De Recherches Servier S.A.S, Suresnes, France
  • Janssen Pharmaceutica NV, Beerse, Belgium
  • Novo Nordisk A/S, Bagsvaerd, Denmark
  • Sanofi-Aventis Deutschland GMBH, Frankfurt / Main, Germany
Universities, research organisations, public bodies, non-profit groups
  • Academisch Ziekenhuis Groningen, Groningen, Netherlands
  • Academisch Ziekenhuis Leiden - Leids Universitair Centrum, Leiden, Netherlands
  • Azienda Ospedaliero-Universitaria Città della Salute e dell Scienza di Torino, Torino, Italy
  • Centre Hospitalier Regional et Universitaire de Lille, Lille, France
  • Centre National De La Recherche Scientifique, Paris, France
  • Eberhard Karls Universitaet Tuebingen, Tuebingen, Germany
  • Imperial College of Science, Technology and Medicine, London, United Kingdom
  • Institut National De La Sante Et De La Recherche Medicale, Paris, France
  • Itä-Suomen yliopisto, Kuopio, Finland
  • Københavns Universitet (University of Copenhagen), Copenhagen, Denmark
  • Lunds Universitet, Lund, Sweden
  • SIB Institut Suisse De Bioinformatique, CH-660-0733998-3, Genève, Switzerland
  • STICHTING VUmc, Amsterdam, Netherlands
  • Technische Universitat Dresden, Dresden, Germany
  • Universita Di Pisa, Pisa, Italy
  • University of Dundee, Dundee, United Kingdom
  • University of Oxford, Oxford, United Kingdom
  • Université Libre de Bruxelles, Bruxelles, Belgium
  • Université Paris Diderot-Paris 7, Paris, France
  • Université de Lausanne, Lausanne, Switzerland
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
  • Lipotype GmbH, Dresden, Germany
  • SCIPROM Sàrl, St-Sulpice, Switzerland
Third parties
  • Université Lille 2 Droit et Santé, Lille, France

CONTACT

Project coordinator
Bernard Thorens
Université de Lausanne
Bernard.Thorens[at]unil.ch